We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Earlier U.S. FDA-Devicemaker Talks Could Ease 522 Postmarket Study Process
Earlier U.S. FDA-Devicemaker Talks Could Ease 522 Postmarket Study Process
April 3, 2012
The U.S. Food and Drug Administration (FDA) will consider adding a mandatory pre-522 discussion period before issuing postmarket surveillance orders, officials at a March 7 FDA public workshop on the process said.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor